TORONTO, Aug. 13, 2012 /PRNewswire/ - Patheon Inc. (TSX: PTI), a leading
provider of contract development and manufacturing services to the
global pharmaceutical industry, announced today that Mark J. Kontny,
Ph.D., President, Global Pharmaceutical Development Services and Chief
Scientific Officer, is no longer with the company, effective as of this
date. Until a replacement has been appointed, Dr. Kontny's duties will
be managed by Patheon's existing PDS operations team.
Patheon Inc. (TSX: PTI) is a leading global provider of contract
development and manufacturing services to the global pharmaceutical
industry. The company provides the highest quality products and
services to approximately 300 of the world's leading pharmaceutical and
biotechnology companies. Its services range from preclinical
development through commercial manufacturing of a full array of dosage
forms including parenteral, soft gel, solid and liquid forms.
The company's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization.
The company's integrated development and manufacturing network of 10
manufacturing facilities, nine development centers and one clinical
trial material packaging facility across North America and Europe,
enables customer products to be launched with confidence anywhere in
SOURCE Patheon Inc.